Daily digest

Medical news today: Monday, October 26, 2026

A first working cancer vaccine, a new MS pill result, and India cracks down on reusing single-use medical devices

1. 01

   Merck and Moderna's personalised mRNA melanoma vaccine becomes the first cancer vaccine to succeed in a Phase 3 trial

   Source: STAT (STAT+, paywalled)

   At the ESMO cancer congress in Madrid, Merck and Moderna presented the first successful late-stage (Phase 3) trial of a cancer vaccine: intismeran, an mRNA vaccine custom-made for each patient's tumour, cut the risk of melanoma returning or death by 42% when added to the immunotherapy Keytruda, compared with Keytruda alone. STAT reports experts are now asking how widely the approach could work in other cancers. Full story is behind the STAT+ paywall.

   Why it mattersAfter decades of failed attempts, this is the first strong proof that a vaccine built from a person's own tumour can help keep a deadly skin cancer (melanoma) from coming back, and it could open the door for other cancers. More on Drug & device safety →
2. 02

   Novartis's remibrutinib pill cuts multiple sclerosis relapses versus teriflunomide in two Phase 3 trials, with no liver safety signal

   Source: MedPage Today

   In the twin REMODEL-1 and REMODEL-2 trials (about 2,000 people with relapsing MS), twice-daily remibrutinib, a BTK inhibitor (a pill that calms certain immune cells), lowered yearly relapse rates by roughly a third compared with the existing MS pill teriflunomide (Aubagio) and sharply reduced new brain lesions on MRI. Unlike some other drugs in its class, no liver-injury signal was seen, though mild bleeding events, mostly skin bruising, were more common (12.7% vs 6.7%). Novartis says it plans to seek approval worldwide; results were also published in The Lancet.

   Why it mattersMultiple sclerosis (MS) affects millions of mostly young adults worldwide, and a new oral option that reduces flare-ups without the liver problems that have dogged similar drugs could widen treatment choices. More on Approvals & regulatory →
3. 03

   India's health directorate orders states to stop hospitals reusing single-use medical devices

   Source: NDTV

   India's Directorate General of Health Services (DGHS), in a letter dated 16 October, told states and Union Territories to strictly enforce a ban on sterilising and reusing devices meant for one use, after reports that some private and corporate hospitals did so in cardiology, oncology, nephrology and neurosurgery, sometimes still charging patients the full price. It cites risks of cross-infection and device failure. A surgeon quoted by NDTV warns the rule could sharply raise the cost of some procedures.

   Why it mattersPatients in India having invasive procedures gain stronger protection against infection and faulty devices, but may face higher bills; NDTV notes patients can ask their care team whether devices are single-use. More on Oncology →
4. Advertise here · reach a global health-curious audience →
5. 04

   Young adults with cancer often delay care and say doctors dismissed their warning signs, US study finds

   Source: Medical Xpress (University at Buffalo)

   Interviews with 30 people diagnosed with cancer between ages 20 and 39, published in Cancer Causes & Control, found many waited months or years before seeing a doctor because they blamed symptoms on stress or found reassuring advice online, and that doctors often brushed off classic warning signs such as rectal bleeding or persistent headaches. The researcher suggests using AI to prepare a symptom timeline and questions for appointments rather than for self-diagnosis.

   Why it mattersCancer is becoming more common in young adults, and the message for anyone is that a symptom that won't go away, like a lump or unusual bleeding, deserves a proper check, and it's fine to push for tests. More on Oncology →
6. 05

   WHO helps Bangladesh assess medicine supply chains to cut shortages of essential medicines

   Source: WHO

   Bangladesh's Directorate General of Health Services, with WHO support, assessed 16 public health facilities between 13 September and 5 October on medicine storage, stock-keeping and an electronic logistics system (eLMIS) already used in 84 facilities. WHO says procurement delays, inaccurate stock records and poor storage contribute to shortages and higher out-of-pocket costs; early recommendations include staff training, better storage and less duplicate paper reporting.

   Why it mattersWhen public clinics run out of medicines, patients pay more out of pocket or go without, so better tracking of stocks could mean more reliable access to treatment for millions. More on Infectious disease →

   Market news · Not investment advice

7. 06

   Somalia and health partners agree priorities, including a new national medicines regulator and Ebola preparedness

   Source: WHO EMRO

   After a joint review in Mogadishu (19 to 21 October), Somalia's health ministry and partners agreed to improve where health facilities and workers are placed, strengthen surveillance, immunisation and emergency preparedness, including for active outbreaks such as Ebola, and plan for climate shocks like El Niño. Participants welcomed a new law (No. 55/2026) creating a national authority to regulate the quality, safety, import and storage of medicines.

   Why it mattersA national medicines regulator is a basic safeguard against fake or poor-quality drugs, and stronger outbreak preparedness in the Horn of Africa matters while Ebola is spreading in the region. More on Approvals & regulatory →
8. Advertise here · reach a global health-curious audience →
9. 07

   World Polio Day: WHO says wild polio is down to 52 cases last year, only in Afghanistan and Pakistan

   Source: WHO EMRO

   At World Polio Day events in Cairo on 24 October, WHO's Eastern Mediterranean office noted that polio paralysed an estimated 350,000 children a year in 1988, versus 52 wild poliovirus cases worldwide last year, all in Afghanistan and Pakistan. Officials called for stronger cross-border work, trusted community leaders and women health workers, and closer links with routine childhood vaccination to finish the job.

   Why it mattersPolio is close to being wiped out, but as long as it survives anywhere, unvaccinated children everywhere remain at risk, which is why routine vaccination still matters. More on Infectious disease →
10. 08

    Smiling more often may lift your mood and help social connection, experts say

    Source: Medical Xpress (AP)

    An Associated Press feature reports that psychologists, including Stanford's Jeanne Tsai, point to research on the 'facial feedback' idea, that physically smiling can make people feel more amused or positive, and say smiling often may help people form friendships. Experts note the effect may partly come from social interaction or recalling good memories.

    Why it mattersIt's a free, low-effort habit that may give a small boost to mood and connection, though it isn't a treatment for depression or other mental health conditions. More on Drug & device safety →
11. 09

    Dermaself takes its selfie-based AI skin analysis into remote skincare efficacy studies

    Source: Cosmetics Business (company-reported)

    Milan-based beauty-tech company Dermaself, whose AI measures more than 60 visible skin parameters from a selfie to recommend routines, says testing labs can now use the same measurement to run skincare efficacy studies on up to 10,000 volunteers photographing their skin at home. The company says the skin classification was validated by research institute Derming on over 100,000 clinical images reviewed by dermatologists.

    Why it mattersClaims like 'clinically shown to reduce wrinkles' may increasingly come from at-home, phone-photo studies, so shoppers may want to look at how a skincare claim was actually tested. More on Cosmetics & skincare →
12. Advertise here · reach a global health-curious audience →
13. 10

    Symrise to present placebo-controlled study of acerola supplement for skin radiance in women aged 45 to 60

    Source: Nutrition Insight (company-reported)

    Ingredient maker Symrise says an unpublished randomised, placebo-controlled study in 108 women aged 45 to 60 found that 600 mg a day of its acerola (a vitamin C-rich cherry) ingredient Acerowell for 12 weeks improved measured skin radiance and translucency versus placebo, with over 80% of users reporting improvements in luminosity and texture. The data are being presented at the SupplySide Global trade show.

    Why it matters'Beauty from within' supplements are a fast-growing market, but these are company-reported, not-yet-published results on cosmetic appearance only, so treat marketing claims with caution. More on Journal papers →
14. 11

    Merck and Moderna share prices hit after melanoma vaccine data leaked ahead of ESMO

    Source: Fierce Biotech

    Fierce Biotech reports that an unexpected leak of the intismeran trial data forced Merck and Moderna to go public two days early, and both companies' share prices took a hit as investors digested the results. Recurrence-free survival at 24 months was 82.2% with the vaccine plus Keytruda versus 70% with Keytruda alone, in line with expectations, but the reduction in cancer spreading to distant organs fell short of what earlier Phase 2 data had suggested.

    Why it mattersIt shows how even a historic medical win can disappoint investors when results land below hopes, which can shape how much money flows into cancer vaccine research. Not investment advice. More on Oncology →

    Market news · Not investment advice